-- Preliminary unaudited net revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of ...
-- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 -- -- Completed enrollment in the Phase 2 trial of ...
Rhythm Pharmaceuticals reports estimated $42 million Q4 and $130 million full year 2024 revenues for IMCIVREE, with clinical trial advancements. Rhythm Pharmaceuticals, Inc. reported preliminary ...
-- Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program-- -- Top-line data readout for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback